# Novocure

Source: https://onco.cc/companies/novocure/  
OnCo record `novocure` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Novocure makes Optune tumour treating fields, approved in glioblastoma, lung, mesothelioma, and (2026) pancreatic cancer.

## Summary

Novocure, based in Root, Switzerland, and listed as NVCR, makes Optune tumour treating fields, approved in glioblastoma, lung cancer, mesothelioma and, in 2026, pancreatic cancer. Its devices are Optune Gio, Optune Lua and Optune Pax, with EF-14 in glioblastoma and PANOVA-3 in pancreatic cancer as the pivotal trials linked, and trials continue in brain metastases and gastric cancer; Zai Lab is its partner in China. OnCo links it to glioma, mesothelioma and pancreatic ductal adenocarcinoma, to the tumour treating fields technology, to the Lurie and Zurich cancer centres, and to the brain as a bottleneck. Whether clinicians adopt a device therapy as readily as a drug is the open question. Optune has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Root
- Type: devices
- Website: https://www.novocure.com
- Ticker: NVCR

## Sources

- Official website: https://www.novocure.com

## Connected records

- fronts: [Devices & Physical Therapies](https://onco.cc/fronts/devices/)
- drugs: [Optune / Optune Pax (TTFields)](https://onco.cc/drugs/optune/)
- trials: [EF-14](https://onco.cc/trials/ef-14/), [EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma](https://onco.cc/trials/nct06556563/), [LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC](https://onco.cc/trials/nct06216301/), [PANOVA-3](https://onco.cc/trials/panova-3/), [STELLAR](https://onco.cc/trials/stellar/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- key papers: [Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study](https://onco.cc/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/)
- roadmaps: [Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants](https://onco.cc/roadmaps/devices-roadmap/), [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- technologies: [Tumour treating fields (TTFields)](https://onco.cc/technologies/ttfields/)
- bottlenecks: [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/)
- institutions: [Robert H. Lurie Comprehensive Cancer Center of Northwestern University](https://onco.cc/institutions/northwestern-lurie/), [University Hospital Zurich / Comprehensive Cancer Center Zurich](https://onco.cc/institutions/usz-zurich/)
- companies: [Zai Lab](https://onco.cc/companies/zai-lab/)

---
JSON: https://onco.cc/api/v1/entities/novocure.json